<?xml version="1.0" encoding="UTF-8"?>
<ref id="cam41388-bib-0015">
 <label>15</label>
 <mixed-citation publication-type="journal" id="cam41388-cit-0015">
  <string-name>
   <surname>Gladkov</surname>, 
   <given-names>O.</given-names>
  </string-name>, 
  <string-name>
   <given-names>V.</given-names>
   <surname>Moiseyenko</surname>
  </string-name>, 
  <string-name>
   <given-names>I. N.</given-names>
   <surname>Bondarenko</surname>
  </string-name>, 
  <string-name>
   <given-names>Y.</given-names>
   <surname>Shparyk</surname>
  </string-name>, 
  <string-name>
   <given-names>S.</given-names>
   <surname>Barash</surname>
  </string-name>, 
  <string-name>
   <given-names>L.</given-names>
   <surname>Adar</surname>
  </string-name>, et al. 
  <year>2016</year>
  <article-title>A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel</article-title>. 
  <source>Oncologist</source>
  <volume>21</volume>:
  <fpage>7</fpage>–
  <lpage>15</lpage>.
  <pub-id pub-id-type="pmid">26668251</pub-id>
 </mixed-citation>
</ref>
